Literature DB >> 26285460

[OSTEOPOROSIS AND PERSONALIZED MEDICINE].

J Y Reginster, A Neuprez, M P Lecart, C Beaudart, F Buckinx, J Slomian, O Bruyère.   

Abstract

Osteoporosis is at the very early stages of the implementation of personalized medicine. However, the development of FRAX®, an algorithm offering the opportunity to calculate, in an individual patient, his/her 10-year fracture risk improves the decision process on the appropriateness to initiate a pharmacological treatment. This algorithm helps the physician to select drugs which are active on non-vertebral fractures only in high risk patients. Taking into consideration patients' preferences, when selecting a therapeutic option, will improve long term adherence and subsequently efficacy and efficiency of the treatments. Attempts to define the natural course of osteoporosis or the response to therapy in individual patients by assessing their genetic profile remains, so far, inconclusive.

Entities:  

Mesh:

Year:  2015        PMID: 26285460

Source DB:  PubMed          Journal:  Rev Med Liege        ISSN: 0370-629X


  1 in total

1.  Scores versus clinical profiles in therapeutic decisions: a positive example from the Italian Medicines Agency (AIFA) decisions in the field of osteoporosis.

Authors:  Antonio Del Puente; Antonella Esposito; Luisa Costa; Francesco Caso; Raffaele Scarpa
Journal:  Clin Rheumatol       Date:  2018-01-29       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.